INS068 is a novel, soluble, long-acting insulin analog developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd., intended to cover basal insulin requirements in patients with T1DM and T2DM. This evidence concerns the gene INS and type 2 diabetes mellitus.